[go: up one dir, main page]

AR084663A1 - Preparados liofilizados de inhibidores de proteasomas - Google Patents

Preparados liofilizados de inhibidores de proteasomas

Info

Publication number
AR084663A1
AR084663A1 ARP100101126A ARP100101126A AR084663A1 AR 084663 A1 AR084663 A1 AR 084663A1 AR P100101126 A ARP100101126 A AR P100101126A AR P100101126 A ARP100101126 A AR P100101126A AR 084663 A1 AR084663 A1 AR 084663A1
Authority
AR
Argentina
Prior art keywords
solution
compound
preparation
formula
lyophilized
Prior art date
Application number
ARP100101126A
Other languages
English (en)
Original Assignee
Cephalon Inc
Cephalon France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Cephalon France filed Critical Cephalon Inc
Publication of AR084663A1 publication Critical patent/AR084663A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen preparados liofilizados de inhibidores de proteasomas así como también métodos para su preparación y uso.Reivindicación 1: Un preparado liofilizado que comprende: (a) un fármaco, en el cual el fármaco es un compuesto de fórmula (1), fórmula (2) o una sal o éster farmacéuticamente aceptable de éste, donde R1 es un heteroarilo de 5, 6 ó 10 miembros opcionalmente sustituido con al menos un N, o R1 es un arilo de 6 ó 10 miembros opcionalmente sustituido; (b) una ciclodextrina; y (e) al menos un miembro seleccionado del grupo conformado por agentes espesantes y surfactantes. Reivindicación 5: El preparado liofilizado de la reivindicación 4, donde el agente espesante es un monosacárido, un oligosacárido, un alcohol de azúcar, un aminoácido o mezclas de éstos. Reivindicación 13: Un método para fabricar un preparado liofilizado que comprende: proporcionar una primera solución que comprende una ciclodextrina, un agente espesante y agua; mezclar un surfactante y una porción de la primera solución para formar una segunda solución; combinar el compuesto de fórmula (1) y la segunda solución para formar una solución del compuesto; mezclar el resto de la primera solución con la solución del compuesto para formar una solución de preliofilización; y liofilizar la solución de preliofilización. Reivindicación 15: Un método para tratar leucemia linfocítica crónica, enfermedad de Hodgkin, linfoma no hodgkiniano, mieloma múltiple o cáncer de mama que comprende administrar a un paciente que lo requiera una cantidad terapéuticamente eficaz de un preparado, preparado a partir de una composición de acuerdo con la reivindicación 4.
ARP100101126A 2009-04-03 2010-04-05 Preparados liofilizados de inhibidores de proteasomas AR084663A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16652909P 2009-04-03 2009-04-03
EP09305291A EP2238973A1 (en) 2009-04-07 2009-04-07 Lyophilized preparations of proteasome inhibitors
US28895509P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
AR084663A1 true AR084663A1 (es) 2013-06-05

Family

ID=41130433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101126A AR084663A1 (es) 2009-04-03 2010-04-05 Preparados liofilizados de inhibidores de proteasomas

Country Status (16)

Country Link
US (1) US8785418B2 (es)
EP (2) EP2238973A1 (es)
JP (1) JP5722871B2 (es)
KR (1) KR20120016082A (es)
CN (1) CN102387790B (es)
AR (1) AR084663A1 (es)
AU (1) AU2010232632C1 (es)
BR (1) BRPI1006633A2 (es)
CA (1) CA2757463A1 (es)
CL (1) CL2011002460A1 (es)
IL (1) IL215325A (es)
MX (1) MX2011010422A (es)
NZ (1) NZ596056A (es)
TW (1) TWI484981B (es)
WO (1) WO2010114982A2 (es)
ZA (1) ZA201107852B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2516449A1 (en) * 2009-12-22 2012-10-31 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
WO2011116286A2 (en) * 2010-03-18 2011-09-22 Innopharma, Llc Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
AU2011312264B2 (en) 2010-10-05 2015-07-02 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
MX2013015308A (es) * 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
CA2784240C (en) * 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
EA021179B1 (ru) * 2012-06-15 2015-04-30 Ощество С Ограниченной Ответственностью "Тева" Лиофилизат соединения бороновой кислоты
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
WO2014102755A1 (en) * 2012-12-31 2014-07-03 Shilpa Medicare Limited Bortezomib formulations
CN103070835B (zh) * 2013-01-31 2015-01-07 江苏奥赛康药业股份有限公司 一种含硼替佐米的冻干组合物及其制备方法
WO2014161072A1 (en) * 2013-04-02 2014-10-09 The Governing Council Of The University Of Toronto Α-boryl isocyanides, boropeptides and boron heterocycles
CN103212055B (zh) * 2013-04-19 2014-11-05 海南锦瑞制药股份有限公司 一种硼替佐米的药物组合物及其制备方法
JP6173495B2 (ja) * 2013-05-29 2017-08-02 ゲア・プロセス・エンジニアリング・アクティーゼルスカブ トロリに収容されたトレイ内の製品の直列滅菌凍結乾燥を実現する方法、方法を実施するためのシステム、および方法の使用
CN103720666B (zh) * 2013-12-16 2015-11-25 亿腾药业（泰州）有限公司 一种注射用硼替佐米冻干制剂的制备方法
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
CN106176637A (zh) * 2016-08-24 2016-12-07 江苏豪森药业集团有限公司 硼替佐米的冻干制剂及其制备方法
AU2017382281B2 (en) * 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
RU2659160C1 (ru) * 2017-07-10 2018-06-28 Акционерное Общество "Фарм-Синтез" Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835968B2 (ja) 1974-02-25 1983-08-05 帝人株式会社 サイクロデキストリン包接化合物の製造法
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
JPS5920230A (ja) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
JPS62281855A (ja) 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
GB8813682D0 (en) 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
JPH035438A (ja) 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
CA2013485C (en) 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
JP3176716B2 (ja) * 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
FR2684875B1 (fr) 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
US5866162A (en) 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6077871A (en) 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
CA2435124A1 (en) * 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
RS65253B1 (sr) 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
DE602005026556D1 (de) * 2004-12-07 2011-04-07 Proteolix Inc Zusammensetzung zur proteasomhemmung
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
DE602006015837D1 (de) * 2005-10-14 2010-09-09 Janssen Pharmaceutica Nv Formulierungen von tipifarnib zur intravenösen verabreichung
AU2007321977A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors

Also Published As

Publication number Publication date
AU2010232632B2 (en) 2016-04-21
JP2012522795A (ja) 2012-09-27
AU2010232632A1 (en) 2011-11-24
IL215325A0 (en) 2011-12-29
WO2010114982A2 (en) 2010-10-07
ZA201107852B (en) 2012-07-25
CA2757463A1 (en) 2010-10-07
CL2011002460A1 (es) 2012-09-14
EP2413916A2 (en) 2012-02-08
MX2011010422A (es) 2011-10-17
AU2010232632C1 (en) 2016-09-22
BRPI1006633A2 (pt) 2019-09-24
CN102387790A (zh) 2012-03-21
IL215325A (en) 2016-06-30
JP5722871B2 (ja) 2015-05-27
KR20120016082A (ko) 2012-02-22
TWI484981B (zh) 2015-05-21
US8785418B2 (en) 2014-07-22
TW201039865A (en) 2010-11-16
EP2238973A1 (en) 2010-10-13
US20120035133A1 (en) 2012-02-09
WO2010114982A3 (en) 2011-09-01
NZ596056A (en) 2012-10-26
CN102387790B (zh) 2014-12-10

Similar Documents

Publication Publication Date Title
AR084663A1 (es) Preparados liofilizados de inhibidores de proteasomas
ES2658953T3 (es) Combinaciones y usos de los mismos
CL2024002023A1 (es) Inhibidor del inflamosoma nlrp3 y uso del mismo
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
UY32062A (es) Inhibidores de beta-secretasa
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CL2011000653A1 (es) Compuestos derivados del acido 1-amino-2-ciclobutil-etil-boronico; composicion farmaceutica; polvo liofilizado y metodo para obtenerlo; y uso en el tratamiento del cancer.
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
MX351975B (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
ECSP13013087A (es) Compuestos para el tratamiento de la adicción
AR077436A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables.
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
BR112013025634A2 (pt) inibidores de hsp90
AR063587A1 (es) Preparcion liquida que comprende pimobendan
PE20061107A1 (es) Composiciones de tigeciclina y metodos para su preparacion
EA201391337A1 (ru) Ингибиторы hsp90
RU2011153353A (ru) Кетолидные соединения, обладающие противомикробной активностью
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
AR066544A1 (es) Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica.
BR112013028679A2 (pt) inibidores do vírus da hepatite c
UY33473A (es) Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
RU2015122032A (ru) Оксазолидинонсодержащие соединения, композиции и способы их использования
EA201101139A1 (ru) Противовоспалительный макролид

Legal Events

Date Code Title Description
FB Suspension of granting procedure